|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
AU752494B2
(en)
|
1998-02-25 |
2002-09-19 |
Dow Chemical Company, The |
High affinity humanized ANTI-CEA monoclonal antibodies
|
|
HUP0104865A3
(en)
*
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
KR100945108B1
(ko)
|
2001-06-13 |
2010-03-02 |
젠맵 에이/에스 |
표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
WO2006031221A1
(en)
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
|
WO2010114129A1
(ja)
|
2009-04-03 |
2010-10-07 |
国立大学法人愛媛大学 |
Ｔ細胞レセプター及び該レセプターをコードする核酸
|
|
CA2770174A1
(en)
|
2009-08-31 |
2011-03-03 |
Roche Glycart Ag |
Affinity-matured humanized anti cea monoclonal antibodies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
KR101981342B1
(ko)
|
2011-03-02 |
2019-05-22 |
로슈 글리카트 아게 |
Cea 항체
|
|
WO2013054320A1
(en)
*
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
PT3199552T
(pt)
|
2012-11-20 |
2020-03-25 |
Sanofi Sa |
Anticorpos anti-ceacam5 e suas utilizações
|
|
KR102955556B1
(ko)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014131694A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
AU2014386824B2
(en)
|
2013-03-15 |
2019-05-09 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
EP3027204B1
(en)
|
2013-07-29 |
2022-01-05 |
2seventy bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
EP3858379A1
(en)
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
|
KR20240164967A
(ko)
|
2014-02-04 |
2024-11-21 |
카이트 파마 인코포레이티드 |
B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
|
|
CA2967222C
(en)
|
2014-11-12 |
2023-10-31 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
US20170296623A1
(en)
|
2014-12-17 |
2017-10-19 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
|
CN204537344U
(zh)
|
2015-01-29 |
2015-08-05 |
西门子瑞士有限公司 |
通知设备
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3262166A4
(en)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
WO2016142532A1
(en)
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
US20190119385A1
(en)
|
2015-03-27 |
2019-04-25 |
University Of Southern California |
Hla-g as a novel target for car t-cell immunotherapy
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
EP3377523A4
(en)
|
2015-11-19 |
2019-06-19 |
The Regents of The University of California |
CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
|
|
EP3380602A4
(en)
|
2015-11-23 |
2019-09-25 |
Trustees of Boston University |
METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
|
|
WO2017091905A1
(en)
|
2015-12-02 |
2017-06-08 |
Innovative Targeting Solutions Inc. |
Single variable domain t-cell receptors
|
|
US20190241910A1
(en)
|
2016-03-11 |
2019-08-08 |
Bluebird Bio, Inc. |
Genome edited immune effector cells
|
|
CA3029121A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
EP3263595A1
(en)
|
2016-06-30 |
2018-01-03 |
Medizinische Hochschule Hannover |
Fusion protein for use in the treatment of hvg disease
|
|
CA3034093A1
(en)
|
2016-08-23 |
2018-03-01 |
The Regents Of The University Of California |
Proteolytically cleavable chimeric polypeptides and methods of use thereof
|
|
KR102397771B1
(ko)
|
2016-09-23 |
2022-05-13 |
프레드 헛친슨 켄서 리서치 센터 |
부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
|
|
MX2019003462A
(es)
|
2016-09-28 |
2019-08-16 |
Gavish Galilee Bio Appl Ltd |
Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
|
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
WO2018148454A1
(en)
|
2017-02-09 |
2018-08-16 |
The Regents Of The University Of California |
Chimeric t cell antigen receptors and methods of use thereof
|
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
SG11201908784TA
(en)
|
2017-03-27 |
2019-10-30 |
Hoffmann La Roche |
Improved antigen binding receptor formats
|
|
EP4759318A2
(en)
|
2017-04-14 |
2026-06-17 |
The General Hospital Corporation |
Chimeric antigen receptor t cells targeting the tumor microenvironment
|
|
GB201707783D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
WO2018211244A1
(en)
|
2017-05-15 |
2018-11-22 |
Autolus Limited |
A cell comprising a chimeric antigen receptor (car)
|
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
KR102742220B1
(ko)
|
2017-09-19 |
2024-12-17 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
항-hla-a2 항체 및 그 사용 방법
|
|
US11814432B2
(en)
|
2017-09-20 |
2023-11-14 |
The University Of British Columbia |
Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
|
|
PL3688155T3
(pl)
|
2017-09-28 |
2023-09-11 |
Immpact-Bio Ltd. |
Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
EP3707166A4
(en)
|
2017-11-06 |
2021-11-24 |
Daniel J. Monticello |
CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
|
|
CN108219004A
(zh)
|
2018-02-08 |
2018-06-29 |
吉林省拓华生物科技有限公司 |
双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
|
|
JP2021520209A
(ja)
*
|
2018-04-04 |
2021-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における腫瘍抗原を検出するための診断アッセイ
|
|
WO2019241549A1
(en)
|
2018-06-15 |
2019-12-19 |
A2 Biotherapeutics, Inc. |
Foxp3-expressing car-t regulatory cells
|
|
BR112021006100A2
(pt)
*
|
2018-09-28 |
2021-07-20 |
Immpact-Bio Ltd. |
métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
|
|
JP2022512594A
(ja)
|
2018-10-05 |
2022-02-07 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体（ｃａｒ）の群
|
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
CA3130489A1
(en)
|
2019-02-18 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
|
TW202115125A
(zh)
|
2019-06-26 |
2021-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｃｅａ抗體及其應用
|
|
EP4010377A4
(en)
|
2019-08-09 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
|
|
WO2021030153A2
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
|
EP4017510A4
(en)
|
2019-08-20 |
2023-11-22 |
Senti Biosciences, Inc. |
CHIMERIC INHIBITOR RECEPTOR
|
|
AU2020350205A1
(en)
|
2019-09-18 |
2022-05-12 |
Lamkap Bio Alpha AG |
Bispecific antibodies against CEACAM5 and CD3
|
|
US20220389075A1
(en)
|
2019-11-12 |
2022-12-08 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
WO2021119489A1
(en)
|
2019-12-11 |
2021-06-17 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
WO2021222576A1
(en)
|
2020-05-01 |
2021-11-04 |
A2 Biotherapeutics, Inc. |
Pag1 fusion proteins and methods of making and using same
|
|
WO2021252635A1
(en)
|
2020-06-11 |
2021-12-16 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
|
US20230257441A1
(en)
|
2020-08-13 |
2023-08-17 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
|
US11433100B2
(en)
|
2020-08-20 |
2022-09-06 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
|
|
EP4251176A4
(en)
*
|
2020-11-24 |
2025-01-15 |
A2 Biotherapeutics, Inc. |
Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
|